Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

112 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Abiraterone acetate plus LHRH therapy versus abiraterone acetate while sparing LHRH therapy in patients with progressive, metastatic and chemotherapy-naïve, castration-resistant prostate cancer (SPARE): study protocol for a randomized controlled trial.
Ohlmann CH, Jäschke M, Jaehnig P, Krege S, Gschwend J, Rexer H, Stöckle M. Ohlmann CH, et al. Among authors: rexer h. Trials. 2017 Oct 4;18(1):457. doi: 10.1186/s13063-017-2195-x. Trials. 2017. PMID: 28978327 Free PMC article. Clinical Trial.
[Study on the therapy of castration-resistant prostate cancer: randomized phase II study of abiraterone acetate plus LHRH therapy vs. abiraterone acetate without LHRH therapy in patients with progressive chemotherapy-naïve castration-resistant prostate cancer [SPARE - AP 67/11 of the Association of Urogenital Oncology (AUO)]].
Rexer H. Rexer H. Urologe A. 2014 Nov;53(11):1665-7. doi: 10.1007/s00120-014-3643-9. Urologe A. 2014. PMID: 25297491 Clinical Trial. German. No abstract available.
[Study on the therapy of castration-resistant prostate cancer : Randomized phase II study of abiraterone acetate with LHRH therapy vs. abiraterone acetate without LHRH therapy in patients with progressive chemotherapy-naive castration-resistant prostate cancer (SPARE) - AP 67/11 of the Association of Urogenital Oncology (AUO)].
Rexer H. Rexer H. Urologe A. 2016 May;55(5):665-7. doi: 10.1007/s00120-016-0077-6. Urologe A. 2016. PMID: 27138632 Clinical Trial. German. No abstract available.
[First line therapy for locally advanced or metastatic urothelial cancer : A randomized double blind phase III multicenter study on adjuvant nivolumab therapy versus placebo in patients with invasive high-risk urothelial cancer (CheckMate 274)-AB 58/17 of the AUO].
Rexer H, Ohlmann CH, Gschwend J; AUO. Rexer H, et al. Urologe A. 2017 Oct;56(10):1331-1332. doi: 10.1007/s00120-017-0480-7. Urologe A. 2017. PMID: 28779222 Clinical Trial. German. No abstract available.
Versorgungsforschung in der Uroonkologie – Von der Last zur Lust auf Daten.
König F, Johannsen M, Klier J, Schönfelder R, Eichenauer R, Rexer H, Gschwend J, Suttmann H, Doehn C. König F, et al. Among authors: rexer h. Aktuelle Urol. 2018 Apr;49(2):125. doi: 10.1055/s-0044-101694. Epub 2018 Mar 27. Aktuelle Urol. 2018. PMID: 29587317 German. No abstract available.
Erstlinientherapie beim lokal fortgeschrittenen oder metastasierten Urothelkarzinom: Eine randomisierte, doppelblinde Phase-III-Multicenterstudie zur adjuvanten Nivolumab-Therapie versus Placebo bei Patienten mit invasivem Hochrisiko-Urothelkarzinom (CheckMate 274) – AB 58/17 der AUO.
Rexer H, Ohlmann CH, Gschwend J. Rexer H, et al. Aktuelle Urol. 2018 Aug;49(4):308-309. doi: 10.1055/a-0633-7395. Epub 2018 Aug 7. Aktuelle Urol. 2018. PMID: 30086585 German. No abstract available.
112 results